Cancer nanomedicines: oversold or underappreciated?

Since the approval of liposomal doxorubicin (Doxil) and daunorubicin (DaunoXome) 20 years ago for the treatment of (HIV-related) Kaposi’s sarcoma, significant investment and research efforts have b...

[1]  R. Kok,et al.  Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. , 2013, Advanced drug delivery reviews.

[2]  G. Storm,et al.  Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo , 2015, The Prostate.

[3]  Ian D. McGilvray,et al.  Mechanism of hard nanomaterial clearance by the liver , 2016, Nature materials.

[4]  Kinam Park,et al.  Analysis on the current status of targeted drug delivery to tumors. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[5]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[6]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[7]  Andrew T. Lucas,et al.  Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[8]  Koen Raemdonck,et al.  Lessons in simplicity that should shape the future of drug delivery , 2015, Nature Biotechnology.

[9]  S. Alzghari,et al.  Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Paul Polakis,et al.  Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.

[11]  R. Vile,et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  Pieter Vader,et al.  Extracellular vesicles as drug delivery systems: lessons from the liposome field. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Fabian Kiessling,et al.  Cancer nanomedicine: Is targeting our target? , 2016, Nature reviews. Materials.

[14]  Jennifer I. Hare,et al.  Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. , 2017, Advanced drug delivery reviews.

[15]  Bert Vogelstein,et al.  Remote loading of preencapsulated drugs into stealth liposomes , 2014, Proceedings of the National Academy of Sciences.